One such example could be the delivery of DNA-damaging pyrrolobenzadiazepine (PBD) dimers with applications of the D3-GPC2-IgG1 mAb that recognizes a tumor-specific epitope of GPC2 [179]. This evidence concerns the gene GPC2 and neoplasm.